Printer Friendly

MARION MERRELL DOW TAKES STEP TO OFFER ADDITIONAL TUBERCULOSIS TREATMENT IN UNITED STATES

 KANSAS CITY, Mo., July 1 /PRNewswire/ -- Marion Merrell Dow Inc. (NYSE: MKC) today announced it has submitted a New Drug Application in the United States for Rifater(R), a triple-combination therapy for tuberculosis.
 Marion Merrell Dow is one of the world's leaders in the treatment of tuberculosis, which is more prevalent in other countries than in the United States. Rifater combines the three drugs most commonly used to treat tuberculosis: rifampin, discovered by Marion Merrell Dow and marketed as a solo therapy under the brand name Rifadin(R); isoniazid; and pyrazinamide. Standard regimens for treating TB call for various combinations of these drugs taken over several months.
 "This is an effort to help stem the resurgence of TB," said Fred W. Lyons, Jr., president and chief executive officer. "Rifater has orphan drug status in the U.S. due to the relatively small number of patients, estimated at 26,000 cases annually. While it is not a major market in the U.S., we believe that offering Rifater is the right thing to do to help these patients."
 In the United States, tuberculosis has been growing in recent years. Patient compliance (or follow-through on the prescribed course of drug therapy) is a major problem because TB patients often are not in regular contact with physicians or clinics. Besides lessening the effectiveness of treatment, failure to follow the regimen can lead to development of drug-resistant TB. Health authorities believe Rifater may help patients comply because it is one product, taken once-a-day, in place of three separate drugs.
 "We are working closely with the Food and Drug Administration and public health authorities to make Rifater available as soon as possible," Lyons said.
 Marion Merrell Dow is a research-based global pharmaceutical organization dedicated to improving the longevity and quality of human life. The company is involved in the discovery, development, manufacture and sale of pharmaceutical products worldwide.
 -0- 7/1/93
 /CONTACT: David M. Thompson or Richard M. Johnson of Marion Merrell Dow, 816-966-4000/
 (MKC)


CO: Marion Merrell Dow Inc. ST: Missouri IN: MTC SU:

MC -- DV004 -- 7620 07/01/93 10:22 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 1, 1993
Words:350
Previous Article:DETROIT EDISON'S RELIABILITY COMMITMENT SHOWS RESULTS
Next Article:THE NEW YORK STOCK EXCHANGE AND MERRILL LYNCH PAY TRIBUTE TO WINN-DIXIE FOR 50 YEARS OF CONSECUTIVE DIVIDEND INCREASES
Topics:


Related Articles
IMMULOGIC AND MARION MERRELL DOW SIGN COLLABORATION AGREEMENT TO COMMERCIALIZE IMMULOGIC'S ALLERVAX ALLERGY PRODUCTS
IMMULOGIC AND MARION MERRELL DOW SIGN FINAL ALLERVAX PRODUCT COMMERCIALIZATION AGREEMENT
MARION MERRELL DOW EXERCISES RIGHT TO LICENSE GENSIA ARA COMPOUND
CORTECH AND MARION MERRELL DOW ADD CLINICAL INDICATIONS AND AMEND LICENSE AGREEMENT IN NEUTROPHIL ELASTASE INHIBITOR PROGRAM
MARION MERRELL DOW SIMPLIFIES GLOBAL BUSINESS STRUCTURE, NAMES LEADERS
MARION MERRELL DOW IN-LICENSES TWO DRUGS IN LATE-STAGE TRIALS FROM MERCK & CO.
MARION MERRELL DOW INC. RECEIVES CLEARANCE TO INTRODUCE NEW TB DRUG IN THE U.S.
RIFATER, NEW TRIPLE COMBINATION THERAPY, NOW AVAILABLE TO TREAT TUBERCULOSIS IN THE U.S.
MARION MERRELL DOW INC. TO CO-PROMOTE PRILOSEC(R) WITH ASTRA MERCK INC. IN THE UNITED STATES
MARION MERRELL DOW INC. ANNOUNCES THREE ANDAS FOR MANUFACTURING UNIT OF ITS GENERIC DRUG SUBSIDIARY - THE RUGBY GROUP INC.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters